Re: Farmas USA
INO
La FDA levanta el hold al ensayo de la VGX-3100
Phase 3 study of lead product candidate VGX-3100 for the treatment of cervical dysplasia caused by the human papillomavirus (HPV). Patient recruitment will start immediately.
The hold was instituted pending the submission of additional data supporting the shelf life of the CELLECTRA 5PSP intramuscular immunotherapy delivery device.
«Después de nada, o después de todo/ supe que todo no era más que nada.»